

09/672126

-106-

Abstract

Methods and compositions are provided for extending the clinical utility of IFN- α in the treatment of a variety of viral and proliferative disorders. Among other aspects, the
5 invention provides methods which increase the efficacy of IFN- α treatment and reduce IFN- α treatment-related side effects. In addition, methods are provided for supporting the survival and for activating natural interferon producing cells (IPCs) *in vitro* without exogenous IL-3 or GM-CSF. The invention is based on the discovery that certain CpG and non-CpG ISNAs promote survival and stimulation of IPCs.

09672126-092700